Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | IDO1 | P14902 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13618350 | 0.79 | KDM4E (0.46) | ALDH1A1KDM4EIDO1HPGDGAA | |
| SCHEMBL5563959 | 0.78 | CSF1R (0.50) | PDE5AALDH1A1KDM4EIDO1HPGD | |
| SCHEMBL432305 | 0.75 | ALDH1A1 (0.49) | PDE5AALDH1A1KDM4EHPGDMAPK1 | |
| SCHEMBL163795 | 0.75 | HIF1A (0.44) | PDE5AALDH1A1KDM4EHPGDMAPK1 | |
| SCHEMBL3240192 | 0.75 | MAP2K4 (0.56) | ALDH1A1KDM4EIDO1HPGDGAA | |
| SCHEMBL22359391 | 0.74 | NOTUM (0.53) | ALDH1A1KDM4EIDO1HPGDGAA | |
| SCHEMBL8332364 | 0.73 | PDE5A (0.41) | PDE5AALDH1A1KDM4EHPGDMAPK1 | |
| SCHEMBL14497193 | 0.73 | KDM4E (0.49) | ALDH1A1KDM4EIDO1HPGDGAA | |
| Perlolyrin SCHEMBL3919519 | 0.72 | PDE5A (1.00) | PDE5AKDM4EIDO1 | |
| SCHEMBL30492905 | 0.72 | PDE5A (0.70) | PDE5AALDH1A1KDM4EHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1842332-A | Compounds, compositions and methods | HIF BIO INC (US) | 2006-10-04 | — | — | CN | claimed |
| EP-1646382-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | HIF BIO INC. (US) | 2006-04-19 | — | — | EP | claimed |
| US-20050187276-A1 | Compounds, compositions and methods | BIZBIOTECH CO., LTD. (KR) | 2005-08-25 | — | — | US | claimed |
| WO-2005030121-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | HIF BIO, INC. (US) | 2005-04-07 | — | — | WO | claimed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2017197555-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017107052-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-7754751-B2 | Preferential inhibition of release of pro-inflammatory cytokines | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2010-07-13 | — | — | US | disclosed |
| US-7754751-B2 | Preferential inhibition of release of pro-inflammatory cytokines | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2010-07-13 | — | — | US | disclosed |
| US-20070142449-A1 | Angiogenesis inhibitors | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2007-06-21 | — | — | US | disclosed |
| US-20070142449-A1 | Angiogenesis inhibitors | YUNG SHIN PHARMACEUTICAL IND. CO., LTD. (TW) | 2007-06-21 | — | — | US | disclosed |
| US-7226941-B2 | Compound for treating angiogenesis | HIF BIO, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| CN-1842332-A | Compounds, compositions and methods | HIF BIO INC (US) | 2006-10-04 | — | — | CN | disclosed |
| EP-1646382-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | HIF BIO INC. (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050187276-A1 | Compounds, compositions and methods | BIZBIOTECH CO., LTD. (KR) | 2005-08-25 | — | — | US | disclosed |
| WO-2005030121-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | HIF BIO, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187276-A1 | Compounds, compositions and methods | HIF1A, HIF1AN, EGLN3 | PDE5A 1987/4885ALDH1A1 858/4885KDM4E 881/4885 |
| US-20070142449-A1 | Angiogenesis inhibitors | MTNR1A, MC3R, MTNR1B | PDE5A 2353/4885ALDH1A1 2436/4885KDM4E 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.